MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Roche Investor Update' source. Thu, 09 Feb 2012 01:31:36 +0100 http://www.medworm.com/index.php?rid=5669458&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2012-02-08b.htm Roche released the following statement in response to the announcement by Illumina, Inc. that its Board of Directors has recommended that shareholders not tender their shares to Roche. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5669458 Wed, 08 Feb 2012 06:00:00 +0100 5669458 http://www.medworm.com/index.php?rid=5669457&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2012-02-08.htm Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application for pertuzumab and granted Priority Review. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5669457 Wed, 08 Feb 2012 06:00:00 +0100 5669457 http://www.medworm.com/index.php?rid=5651582&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2012-02-01b.htm Following the publication of Chugai’s official 2011 results, Roche offers this investor update which reconciles these results with the results for Chugai published by Roche as part of the Roche Group’s 2011 results. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5651582 Wed, 01 Feb 2012 13:00:00 +0100 5651582 http://www.medworm.com/index.php?rid=5651583&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2012-02-01.htm Group sales rise 2% 1 (-10% in Swiss francs; +6% in US dollars), excluding Tamiflu; Significant foreign exchange impact of –12 percentage points due to appreciation of the Swiss franc; overall Group sales at 42.5 billion Swiss francs. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5651583 Wed, 01 Feb 2012 06:00:00 +0100 5651583 http://www.medworm.com/index.php?rid=5651584&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2012-01-31.htm Roche announced today that it has provided notice to Illumina, Inc. (NASDAQ: ILMN) that it will nominate a slate of highly qualified, independent candidates for election to Illumina’s Board of Directors and propose certain other matters for the consideration of Illumina’s shareholders at Illumina’s 2012 annual meeting, which, if adopted, would result in Roche-nominated directors comprising a majority of the Illumina board. Roche also named five alternate nominees for election to Illumina’s board. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5651584 Tue, 31 Jan 2012 17:00:00 +0100 5651584 http://www.medworm.com/index.php?rid=5651585&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2012-01-30.htm Roche today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation. Erivedge is the first FDA-approved medicine for people with advanced forms of the most common skin cancer. It is a capsule that is taken orally once-a-day. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5651585 Mon, 30 Jan 2012 17:00:00 +0100 5651585 http://www.medworm.com/index.php?rid=5639974&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2012-01-27b.htm Roche, a leader in research-focused healthcare with combined strengths in pharmaceuticals, life science tools and diagnostics, announced today that it has commenced a cash tender offer to acquire all outstanding shares of Illumina, Inc. (NASDAQ: ILMN). The offer and withdrawal rights are scheduled to expire at 12:00 midnight, New York City time, at the end of the day on February 24, 2012, unless the offer is extended. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5639974 Fri, 27 Jan 2012 16:50:00 +0100 5639974 http://www.medworm.com/index.php?rid=5639975&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2012-01-27.htm Roche today responded to an announcement from Illumina, Inc. (NASDAQ: ILMN) that its Board of Directors has adopted a shareholder rights plan. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5639975 Thu, 26 Jan 2012 23:00:00 +0100 5639975 http://www.medworm.com/index.php?rid=5631219&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2012-01-26.htm First randomised phase III trial evaluating continued use of Avastin with chemotherapy after disease progression meets primary endpoint. Roche announced today that a phase III study (ML 18147) in metastatic colorectal cancer met its primary endpoint of overall survival. People who received Avastin® (bevacizumab) plus standard chemotherapy as initial treatment (so-called “first-line” treatment) for their metastatic colorectal cancer and then continued on Avastin with a different chemotherapy after their cancer progressed (so-called “second-line” treatment) lived significantly longer than people who received only chemotherapy in the second-line setting. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5631219 Thu, 26 Jan 2012 06:00:00 +0100 5631219 http://www.medworm.com/index.php?rid=5631220&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2012-01-25.htm Roche announced today that it is proposing to acquire all outstanding shares of Illumina, Inc. (NASDAQ:ILMN) for $44.50 per share in cash, or an aggregate of approximately $5.7 billion on a fully diluted basis. This offer represents a 64% premium over Illumina’s stock price on December 21, 2011 – the day before market rumors about a potential transaction between Roche and Illumina drove Illumina’s stock price significantly higher – a 61% premium over the one-month historical average and a 43% premium over the three-month historical average of Illumina’s share price, both as of December 21. It also represents a 30.1x multiple of Illumina’s projected forward earnings based upon analysts’ current consensus estimates for 2012. (Source: Roche Investor U... Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5631220 Wed, 25 Jan 2012 02:40:00 +0100 5631220 http://www.medworm.com/index.php?rid=5612269&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2012-01-18.htm Roche will publish its Full Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 1st February 2012 at 7:00 CET / 6:00 GMT / 1:00 AM EST / 10:00PM PST (evening before) (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5612269 Wed, 18 Jan 2012 09:00:00 +0100 5612269 http://www.medworm.com/index.php?rid=5586179&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2012-01-11.htm Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Accu-Chek Nano SmartView blood glucose monitoring system. The new Accu-Chek Nano meter, which is smaller than a standard credit card, employs a large brilliant backlit display and does not require any manual coding or code key for enhanced ease of use. It also offers improved functions such as customizable test reminders, pre- and postmeal markers and average glucose calculation. The Accu-Chek Nano meter uses Accu-Chek SmartView test strips and will be available to customers in the first half of 2012. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5586179 Wed, 11 Jan 2012 17:00:00 +0100 5586179 http://www.medworm.com/index.php?rid=5586180&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2012-01-03.htm Roche will publish its Full Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 1st February 2012 at 7:00 CET / 6:00 GMT / 1:00 AM EST / 10:00PM PST (evening before) (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5586180 Tue, 03 Jan 2012 09:00:00 +0100 5586180 http://www.medworm.com/index.php?rid=5539861&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-12-23.htm Roche announced today that the European Commission has approved Avastin (bevacizumab) in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line (first-line following surgery) treatment for women with advanced ovarian cancer. Ovarian cancer is the most deadly of the gynaecological cancers, with approximately 220,000 women diagnosed and 140,000 women dying from the disease each year globally. The approval of Avastin marks a major advance in the treatment of women with ovarian cancer for whom treatment has been limited to surgery and chemotherapy. "Today's approval of Avastin marks the first major treatment advance in newly diagnosed ovarian cancer in 15 years," said Hal Barron M.D., Chief Medical Officer and Head, Global Product Development. (Sourc... Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5539861 Fri, 23 Dec 2011 06:00:00 +0100 5539861 http://www.medworm.com/index.php?rid=5507603&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-12-16.htm Roche, today announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended that Zelboraf be granted full marketing authorization as a monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5507603 Fri, 16 Dec 2011 12:25:00 +0100 5507603 http://www.medworm.com/index.php?rid=5497020&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-12-12.htm Separate study indicates that GA101 is highly effective in combination with chemotherapy. Roche announced today that its investigational unique type II anti-CD20 antibody GA101 (obinutuzumab) increased the overall response rate (ORR) of patients with relapsed CD20+ indolent non-Hodgkin’s Lymphoma (iNHL), a common type of blood cancer, compared to MabThera/Rituxan (rituximab) in the first head to head comparison. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5497020 Mon, 12 Dec 2011 06:00:00 +0100 5497020 http://www.medworm.com/index.php?rid=5489233&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-12-08b.htm CLEOPATRA, a phase III trial of pertuzumab plus trastuzumab plus docetaxel in first-line treatment of patients with HER2-positive metastatic breast cancer. Friday, 9 December 2011, San Antonio TX, USA. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5489233 Thu, 08 Dec 2011 09:00:00 +0100 5489233 http://www.medworm.com/index.php?rid=5489234&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-12-08.htm Roche today announced results from CLEOPATRA, the first randomised Phase III study of the investigational HER2-targeted medicine pertuzumab. The study compared the combination of pertuzumab, Herceptin (trastuzumab) and docetaxel chemotherapy to Herceptin and docetaxel alone in people with previously untreated HER2-positive metastatic breast cancer (mBC). People who received pertuzumab in combination with Herceptin and chemotherapy experienced a 38 percent reduction in the risk of their disease worsening or death (progression-free survival, or PFS), (HR=0.62; p-value=<0.0001). The median PFS improved by 6.1 months from 12.4 months for Herceptin and chemotherapy to 18.5 months for pertuzumab, Herceptin and chemotherapy. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5489234 Wed, 07 Dec 2011 23:30:00 +0100 5489234 http://www.medworm.com/index.php?rid=5460730&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-12-01.htm New Test allows identification of lung cancer patients who may benefit from early treatment with EGFR inhibitors. Roche announced today that the cobas EGFR Mutation Test is now CE marked for commercial availability in Europe and other countries that recognize CE mark. The cobas EGFR Mutation Test is a companion diagnostic to identify patients with non-small cell lung cancer (NSCLC) who harbor mutations in the EGFR (epidermal growth factor receptor) gene and who may benefit from treatment with anti-EGFR tyrosine kinase inhibitors such as Roche’s Tarceva (erlotinib). (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5460730 Thu, 01 Dec 2011 06:00:00 +0100 5460730 http://www.medworm.com/index.php?rid=5460731&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-11-30b.htm CLEOPATRA, a phase III trial of pertuzumab plus trastuzumab plus docetaxel in first-line treatment of patients with HER2-positive metastatic breast cancer. Friday, 9 December 2011, San Antonio TX, USA. We kindly invite investors and analysts to participate in a conference call that will be held during the San Antonio Breast Cancer Symposium taking place from 6-10 December in San Antonio. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5460731 Wed, 30 Nov 2011 09:00:00 +0100 5460731 http://www.medworm.com/index.php?rid=5460732&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-11-30.htm Roche today announced that it will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer, at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) December 6-10 2011. This includes data from the first randomised Phase III study of pertuzumab in combination with Herceptin and docetaxel chemotherapy (CLEOPATRA). The mechanisms of action of pertuzumab and Herceptin are believed to complement each other as both bind to the HER2 receptor but on different regions. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5460732 Wed, 30 Nov 2011 06:00:00 +0100 5460732 http://www.medworm.com/index.php?rid=5443746&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-11-23.htm Roche today announced that its wholly owned subsidiary Bryce Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender offer for all outstanding shares of common stock of Anadys Pharmaceuticals, Inc. at $3.70 per share in cash. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5443746 Wed, 23 Nov 2011 06:00:00 +0100 5443746 http://www.medworm.com/index.php?rid=5424410&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-11-18.htm U.S. Food and Drug Administration (FDA) Commissioner revokes approval of Avastin for treatment of metastatic breast cancer (mBC) in the United States. This action concludes the FDA’s review of Avastin’s use for mBC. This decision does not impact Avastin’s approved uses for other cancer types in the United States or other countries. This decision also does not impact the approval of Avastin for mBC in more than 80 other countries. Roche will start a new trial of Avastin plus paclitaxel in mBC. Roche announced today that the FDA Commissioner is revoking the approval of Avastin (bevacizumab) for the treatment of mBC in the United States. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5424410 Fri, 18 Nov 2011 16:45:00 +0100 5424410 http://www.medworm.com/index.php?rid=5391464&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-11-09.htm Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed the company’s New Drug Application for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. The application has been granted Priority Review status and the FDA confirmed the action date is March 8, 2012. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5391464 Wed, 09 Nov 2011 06:00:00 +0100 5391464 http://www.medworm.com/index.php?rid=5367739&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-10-31.htm The Roche Investor Relations team would like to invite you to a Late-stage pipeline event that will take place in London on 7 November 2011 starting at 2pm local time. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5367739 Mon, 31 Oct 2011 09:00:00 +0100 5367739 http://www.medworm.com/index.php?rid=5339161&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-10-20.htm Phase III trials underway to investigate ocrelizumab in two forms of MS. Roche today announced 96-week results from a Phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common clinical form of the disease. The study showed that the significant reduction in disease activity as measured by the total number of active brain lesions and relapses previously reported for 24 weeks, was maintained through 96 weeks. The data is being presented today at ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) the world's largest annual international conference devoted to basic and clinical research in multiple sclerosis. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5339161 Thu, 20 Oct 2011 05:00:00 +0100 5339161 http://www.medworm.com/index.php?rid=5326192&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-10-18.htm Phase III study of a quicker route of administration shows comparable results to intravenous Herceptin. Roche today announced that the Phase III HannaH study demonstrated comparable efficacy of a new, investigational subcutaneous (SC) formulation of Herceptin (trastuzumab) to the standard intravenous (IV) infusion of Herceptin in women with HER2-positive early breast cancer. The SC administration takes around 5 minutes to administer whereas the IV formulation (the current standard) takes around 30 minutes to infuse. Since the subcutaneous administration is an injection under the skin it may allow patients to spend less time in hospital receiving their treatment versus the intravenous method. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5326192 Tue, 18 Oct 2011 05:00:00 +0100 5326192 http://www.medworm.com/index.php?rid=5326193&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-10-17.htm Roche and Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) today announced that the two companies have entered into a definitive merger agreement for Roche to fully acquire Anadys at a price of USD 3.70 per share in an all-cash transaction. This corresponds to a total cash consideration of approximately USD 230 million. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5326193 Mon, 17 Oct 2011 05:00:00 +0100 5326193 http://www.medworm.com/index.php?rid=5317609&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-10-13.htm Group sales rise 2% at CER (-12% in Swiss francs; +7% in US dollars), excluding Tamiflu; Significant foreign exchange impact of -13% due to appreciation of Swiss franc; overall Group sales at 31.5 billion Swiss francs (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5317609 Thu, 13 Oct 2011 05:00:00 +0100 5317609 http://www.medworm.com/index.php?rid=5306902&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-10-11.htm The Roche Investor Relations team would like to invite you to a Late-stage pipeline event that will take place in London on 7 November 2011 starting at 2pm local time. The event will provide an opportunity to discuss clinical data and development plans for key late-stage compounds in the Roche development pipeline, including T-DM1 (HER2 franchise) for HER2-positive breast cancer and lebrikizumab (anti-IL13 antibody) for severe asthma. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5306902 Tue, 11 Oct 2011 12:00:00 +0100 5306902 http://www.medworm.com/index.php?rid=5288419&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-10-06.htm Roche will publish its Sales Results for the 3rd Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday 13th October, 2011. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5288419 Thu, 06 Oct 2011 08:00:00 +0100 5288419 http://www.medworm.com/index.php?rid=5276990&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-09-30.htm Roche announced today that it has been awarded an exclusive contract by Karolinska University Hospital in Stockholm, Sweden, to provide a diagnostic tool for primary screening of Human Papillomavirus (HPV) in Swedish women. This is the first major public tender in Europe to screen women using Roche’s HPV test for high risk virus types which potentially can cause cervical cancer. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5276990 Fri, 30 Sep 2011 05:00:00 +0100 5276990 http://www.medworm.com/index.php?rid=5263793&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-09-29.htm Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Accu-Chek Aviva Plus test system. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5263793 Thu, 29 Sep 2011 05:00:00 +0100 5263793 http://www.medworm.com/index.php?rid=5253362&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-09-26b.htm Please find attached a press release by Chugai (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5253362 Mon, 26 Sep 2011 06:00:00 +0100 5253362 http://www.medworm.com/index.php?rid=5253361&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-09-26a.htm Please find attached a press release by Chugai. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5253361 Mon, 26 Sep 2011 06:00:00 +0100 5253361 http://www.medworm.com/index.php?rid=5253363&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-09-25.htm Roche today announced the results of the Phase II study TDM4450g in patients with previously untreated HER2-positive metastatic breast cancer (mBC). (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5253363 Sat, 24 Sep 2011 22:02:00 +0100 5253363 http://www.medworm.com/index.php?rid=5253364&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-09-24.htm Roche today announced that AVAPERL, a phase III study evaluating the combination of Avastin® (bevacizumab) and chemotherapy for patients with previously untreated, advanced non-squamous non-small cell lung cancer (NSCLC) met its primary endpoint, giving lung cancer patients significantly more time without their disease progressing. The results will be presented for the first time today at the European Multidisciplinary Cancer Congress in Stockholm. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5253364 Fri, 23 Sep 2011 22:01:00 +0100 5253364 http://www.medworm.com/index.php?rid=5253365&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-09-23.htm Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Avastin in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5253365 Fri, 23 Sep 2011 11:40:00 +0100 5253365 http://www.medworm.com/index.php?rid=5229054&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-09-19.htm Roche today announced that encouraging data on its investigational and approved medicines will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm being held 23-27 September 2011. Presentations include important new data on Roche’s investigational antibody-drug conjugate trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer and pivotal data on vismodegib an investigational oral drug that targets a specific disease pathway in advanced skin cancer. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5229054 Mon, 19 Sep 2011 05:00:00 +0100 5229054 http://www.medworm.com/index.php?rid=5229055&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-09-14.htm Roche will publish its Sales Results for the 3rd Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday 13th October, 2011. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5229055 Wed, 14 Sep 2011 08:00:00 +0100 5229055 http://www.medworm.com/index.php?rid=5212900&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-09-13.htm We are pleased to invite you to our Roche Diagnostics Investor Day on 21 September at 14:30 BST / 15:30 CET / 9:30 AM EDT at the London Stock Exchange. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5212900 Tue, 13 Sep 2011 08:00:00 +0100 5212900 http://www.medworm.com/index.php?rid=5212901&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-09-08.htm Reinforces commitment to creating long-term value for all stakeholders. Roche announced today that it has been recognized as the most sustainable healthcare company globally in the Dow Jones Sustainability Index (DJSI), for the third year in a row. The DJSI World and DJSI Europe Indexes track the performance of the leading sustainability companies based on environmental, social and economic performance. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5212901 Thu, 08 Sep 2011 09:45:00 +0100 5212901 http://www.medworm.com/index.php?rid=5186708&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-09-02.htm Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama (hereafter, “Chugai”)] announced today that it has entered into license agreements with F. Hoffmann-La Roche, Ltd [Head Office: Basel, Switzerland / CEO: Severin Schwan (hereafter, “Roche”)] covering humanized anti-Met antibody MetMAb, for non-small cell lung cancer (NSCLC) and humanized anti-interleukin(IL)-13 antibody lebrikizumab for bronchial asthma which are both currently developed by Roche utilizing the Personalized Healthcare (PHC) approach and have also entered phase I clinical studies in the Japanese population. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5186708 Fri, 02 Sep 2011 06:00:00 +0100 5186708 http://www.medworm.com/index.php?rid=5186709&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-09-01.htm Personalised Healthcare strategy allows to identify lung cancer patients who benefit from early treatment with Tarceva. Roche announced today that the European Commission has approved Tarceva® (erlotinib) for use in patients with a genetically distinct type of non-small cell lung cancer (NSCLC) in Europe. This approval will enable the use of Tarceva as a first-line monotherapy in people with locally advanced or metastatic NSCLC with EGFR (epidermal growth factor receptor) activating mutations. Tumours with these mutations are responsive to Tarceva and treatment with this medicine has been shown to more than triple the number of patients whose tumours shrink (response rate). (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5186709 Thu, 01 Sep 2011 05:00:00 +0100 5186709 http://www.medworm.com/index.php?rid=5171760&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-08-29.htm Roche announced today results from two exploratory mechanistic Phase IIb studies investigating dalcetrapib’s effects on atherosclerotic disease progression (dal-PLAQUE) and vascular function (dal-VESSEL) in patients with or at risk of coronary heart disease. The studies were presented at the European Society of Cardiology Congress (ESC) and further support the safety profile of the investigational compound dalcetrapib, a first-in-class cholesteryl ester transfer protein (CETP) modulator. "The results of dal-PLAQUE and dal-VESSEL further support the safety profile of dalcetrapib," said Hal Barron M.D., Chief Medical Officer and Head, Global Product Development. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5171760 Mon, 29 Aug 2011 05:00:00 +0100 5171760 http://www.medworm.com/index.php?rid=5165229&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-08-25.htm We kindly invite investors and analysts to participate in a conference call that will be held during the European Society of Cardiology Congress taking place from 27-31 August 2011 in Paris. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5165229 Thu, 25 Aug 2011 08:00:00 +0100 5165229 http://www.medworm.com/index.php?rid=5149529&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-08-22.htm We are pleased to invite you to our Roche Diagnostics Investor Day on 21 September at 14:30 BST / 15:30 CET / 9:30 AM EDT at the London Stock Exchange. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5149529 Mon, 22 Aug 2011 12:00:00 +0100 5149529 http://www.medworm.com/index.php?rid=5149530&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-08-17.htm Roche today announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as determined by an FDA-approved test. The FDA today also approved the cobas 4800 BRAF V600 Mutation Test, a diagnostic test developed by Roche to identify patients eligible for treatment. Zelboraf is the first and only FDA-approved personalized medicine shown to improve survival in people with BRAF V600E mutation-positive metastatic melanoma, demonstrating the benefits of Roche’s personalized healthcare approach. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5149530 Wed, 17 Aug 2011 13:55:00 +0100 5149530 http://www.medworm.com/index.php?rid=5127854&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-08-15b.htm Phase II data from the endothelial function study dal-VESSEL and the imaging study dal-PLAQUE - Monday, 29 August 2011, Paris, France (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5127854 Mon, 15 Aug 2011 08:27:00 +0100 5127854 http://www.medworm.com/index.php?rid=5127855&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-08-15.htm Dear Investor, Please find attached a press release by Chugai. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5127855 Mon, 15 Aug 2011 06:00:00 +0100 5127855 http://www.medworm.com/index.php?rid=5099593&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-08-04.htm Roche today announced that a phase II study of its investigational treatment lebrikizumab, a humanized monoclonal antibody designed to block interleukin-13 (IL-13) cytokine, met its primary endpoint. In the study, lebrikizumab treatment resulted in a statistically significant increase in FEV1 (measure of lung function) in adults with asthma whose symptoms were inadequately controlled with inhaled corticosteriods (ICS). The overall frequency of adverse events was similar in both the placebo and the treatment group. The results of this study, known as ‘MILLY’, are being published in the New England Journal of Medicine (NEJM) today. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5099593 Thu, 04 Aug 2011 05:00:00 +0100 5099593 http://www.medworm.com/index.php?rid=5090425&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-08-03.htm Medicine offers new treatment option for Systemic Juvenile Idiopathic Arthritis (sJIA). Roche announced today that the European Commission has approved the use of RoACTEMRA (tocilizumab) for the treatment of active Systemic Juvenile Idiopathic Arthritis (sJIA) in patients two years of age and older who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids (medicines used to treat inflammation). RoACTEMRA (known as ACTEMRA outside Europe) can be given alone or in combination with methotrexate in patients with sJIA. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5090425 Wed, 03 Aug 2011 05:00:00 +0100 5090425 http://www.medworm.com/index.php?rid=5054573&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-07-22a.htm Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in the EU supporting earlier, frontline use of Tarceva (erlotinib) in people with a genetically distinct type of non-small cell lung cancer (NSCLC). The proposed use of Tarceva is for first-line monotherapy in people diagnosed with advanced EGFR (epidermal growth factor receptor) activating mutation positive NSCLC. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5054573 Fri, 22 Jul 2011 13:20:00 +0100 5054573 http://www.medworm.com/index.php?rid=5054574&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-07-22b.htm Results of Chugai as consolidated by the Roche Group. Following the publication of Chugai’s official 2011 interim results, Roche offers this investor update which reconciles these results with the results for Chugai published by Roche as part of the Roche Group’s 2011 interim results. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5054574 Fri, 22 Jul 2011 08:00:00 +0100 5054574 http://www.medworm.com/index.php?rid=5043461&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-07-21.htm Group sales stable in local currencies. Excluding Tamiflu, Group sales up 2% and Pharmaceuticals Division sales up 1%; Diagnostics Division sales up 5%; on track to meet full-year guidance. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5043461 Thu, 21 Jul 2011 05:00:00 +0100 5043461 http://www.medworm.com/index.php?rid=5043462&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-07-19b.htm Dear Investor, please find attached a press release by Chugai. Do not hesitate to contact us for any further questions. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5043462 Tue, 19 Jul 2011 06:00:00 +0100 5043462 http://www.medworm.com/index.php?rid=5043463&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-07-19.htm Roche announced today that it has signed an agreement under which it will acquire 100 percent of mtm laboratories AG (mtm), a privately-held company based in Heidelberg, Germany. mtm is a global leader in developing in vitro diagnostics with a focus on early detection and diagnosis of cervical cancer, the largest early detection market in oncology. mtm will become part of Roche’s Tissue Diagnostics (Ventana Medical Systems, Inc.) business unit. Under the terms of the agreement, Roche will pay mtm shareholders an upfront payment of approximately 130 million EUR as well as up to approximately 60 million EUR upon reaching performance-related milestones. The transaction is subject to customary closing conditions and is expected to close in the coming weeks. (Source: Roche Investor Update... Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5043463 Tue, 19 Jul 2011 05:00:00 +0100 5043463 http://www.medworm.com/index.php?rid=5032426&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-07-15.htm Roche today announced that CLEOPATRA, a pivotal Phase III study, met its primary endpoint. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5032426 Fri, 15 Jul 2011 05:00:00 +0100 5032426 http://www.medworm.com/index.php?rid=5032427&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-07-14b.htm Roche will publish its Half Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 21st July at 7:00 CET / 6:00 BST / 1:00 AM EDT / 10:00 PM PDT (evening before). (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5032427 Thu, 14 Jul 2011 08:00:00 +0100 5032427 http://www.medworm.com/index.php?rid=5032428&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-07-14.htm Roche announced today two research publications from its Early Development unit gRED outlining how a new technology successfully facilitated transport of an anti-amyloidogenic antibody across the blood-brain barrier and release into the brain. This technology may increase the potential to utilize antibodies in the therapy of brain diseases such as Alzheimer’s disease. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=5032428 Thu, 14 Jul 2011 05:00:00 +0100 5032428 http://www.medworm.com/index.php?rid=4988332&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-07-01.htm Dear Investor, please find attached a press release by Chugai. Do not hesitate to contact us for any further questions. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4988332 Fri, 01 Jul 2011 06:00:00 +0100 4988332 http://www.medworm.com/index.php?rid=4988331&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-07-01b.htm Dear Investor, please find attached a press release by Chugai. Do not hesitate to contact us for any further questions. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4988331 Fri, 01 Jul 2011 06:00:00 +0100 4988331 http://www.medworm.com/index.php?rid=4988334&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-06-30b.htm Expanded label allows combination with Xeloda or paclitaxel in first-line setting. Roche announced today that the European Commission has extended the existing Avastin (bevacizumab) metastatic breast cancer label to include combination with Xeloda (capecitabine). The European Commission had recently confirmed the approval of Avastin in combination with paclitaxel chemotherapy for women with metastatic breast cancer in the first-line setting. This new extension provides an additional first-line treatment option for women in whom treatment with other chemotherapies (including taxanes or anthracyclines) is not considered appropriate. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4988334 Thu, 30 Jun 2011 05:00:00 +0100 4988334 http://www.medworm.com/index.php?rid=4988333&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-06-30.htm FDA Commissioner to Make Final Decision at a Later Date. Roche announced today that, during a U.S. Food and Drug Administration (FDA) hearing on Wednesday, the FDA’s Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin (bevacizumab) in combination with paclitaxel chemotherapy for previously untreated (first-line) HER2-negative metastatic breast cancer. The committee’s recommendation is not the final decision and Avastin plus paclitaxel is still FDA approved for women with HER2-negative metastatic breast cancer. The FDA Commissioner will make the final decision on whether Avastin should remain approved for metastatic breast cancer. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4988333 Thu, 30 Jun 2011 05:00:00 +0100 4988333 http://www.medworm.com/index.php?rid=4979220&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-06-29.htm Two-Year Data from RISE and RIDE studies presented at the American Diabetes Association Annual Scientific Sessions. Genentech, a member of the Roche Group, today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the efficacy and safety of Lucentis® (ranibizumab injection) in people with diabetic macular edema (DME). The data showed patients who received Lucentis experienced significant, rapid and sustained improvement in vision compared to those who received placebo (sham) injections. Additional analyses showed patients who received Lucentis were significantly more likely to achieve 20/40 vision and experience less progression of the underlying diabetic retinopathy disease. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4979220 Wed, 29 Jun 2011 05:00:00 +0100 4979220 http://www.medworm.com/index.php?rid=4963708&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-06-24.htm Roche will publish its Half Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 21st July at 7:00 CET / 6:00 BST / 1:00 AM EDT / 10:00 PM PDT (evening before). (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4963708 Fri, 24 Jun 2011 08:00:00 +0100 4963708 http://www.medworm.com/index.php?rid=4948109&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-06-20.htm Roche announced today that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. Basal Cell Carcinoma is a form of skin cancer that can cause disfiguring and debilitating effects and can ultimately be life-threatening. Vismodegib is an investigational, oral medicine designed to selectively inhibit signalling in the Hedgehog pathway, which is implicated in more than 90 percent of BCC cases. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4948109 Mon, 20 Jun 2011 05:00:00 +0100 4948109 http://www.medworm.com/index.php?rid=4897638&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-06-05.htm Roche’s Personalised Healthcare approach demonstrated through vemurafenib and its investigational companion diagnostic, Roche’s cobas 4800 BRAF V600 Mutation Test. Roche today announced that a Phase III study (BRIM3) showed vemurafenib (RG7204, PLX4032) significantly improved overall survival (OS) in people with previously untreated BRAF V600 mutation-positive metastatic melanoma, compared to chemotherapy. In the study, the risk of death was reduced by 63 percent for people who received vemurafenib compared to those who received chemotherapy (hazard ratio [HR]=0.37, p<0.0001). In addition, vemurafenib significantly reduced the risk of the disease getting worse (progression-free survival, or PFS, a co-primary endpoint), by 74 percent compared to chemotherapy (HR=0.26, p&#06... Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4897638 Sun, 05 Jun 2011 15:00:00 +0100 4897638 http://www.medworm.com/index.php?rid=4897639&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-06-04.htm Phase III OCEANS results add to the growing body of evidence supporting Avastin’s potential role in ovarian cancer. Roche today announced results from OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer. Women who received Avastin experienced a 52 percent reduction in the risk of their disease progressing (HR = 0.48, p<0.0001) compared to women who received chemotherapy alone. Adverse events in OCEANS were consistent with those seen in previous pivotal trials of Avastin across tumor types. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4897639 Sat, 04 Jun 2011 15:30:00 +0100 4897639 http://www.medworm.com/index.php?rid=4897640&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-06-03.htm Roche today announced results of EURTAC, the first Phase III study with Tarceva (erlotinib) in Western patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC). EURTAC showed that first-line Tarceva nearly doubled the time people with NSCLC with EGFR activating mutations lived without their disease getting worse compared with chemotherapy (median progression-free survival or PFS: 9.7 months compared with 5.2 months). Tarceva significantly reduced the risk of the disease getting worse by 63 percent compared with standard chemotherapy (hazard ratio=0.37, p<0.0001). The safety profile for Tarceva was consistent with previous studies in NSCLC. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4897640 Fri, 03 Jun 2011 05:00:00 +0100 4897640 http://www.medworm.com/index.php?rid=4887976&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-06-02.htm Roche today announced that it has entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY) to investigate the combination of vemurafenib with Bristol-Myers Squibb’s ipilimumab in patients with BRAF-mutated metastatic melanoma. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4887976 Thu, 02 Jun 2011 11:00:00 +0100 4887976 http://www.medworm.com/index.php?rid=4867178&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-05-27.htm Analyst briefing on data presented at ASCO: Sunday, 5th June 2011. We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (3-7 June 2011). We will have a significant presence at the congress with almost 300 scientific abstracts submitted. A summary of the key data presented at ASCO will be provided at the Analyst briefing. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4867178 Fri, 27 May 2011 08:00:00 +0100 4867178 http://www.medworm.com/index.php?rid=4867179&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-05-26.htm New study confirms RoACTEMRA is effective when used on its own for people who do not respond to methotrexate. Roche today announced new data from the ACT-RAY study, presented at the European League Against Rheumatism congress. The results demonstrated that in people with rheumatoid arthritis (RA), RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) alone had comparable clinical efficacy to RoACTEMRA plus methotrexate (MTX). The safety profile of RoACTEMRA was consistent with previous clinical trials. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4867179 Thu, 26 May 2011 05:00:00 +0100 4867179 http://www.medworm.com/index.php?rid=4844555&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-05-20.htm Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an extension to the RoActemra (tocilizumab) rheumatoid arthritis label in Europe for the treatment of active Systemic Juvenile Idiopathic Arthritis (sJIA) in patients two years of age and older who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra (known as ACTEMRA outside Europe) can be given alone or in combination with methotrexate in patients with sJIA. Final approval from the European Commission is expected in July 2011. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4844555 Fri, 20 May 2011 15:00:00 +0100 4844555 http://www.medworm.com/index.php?rid=4857184&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-05-20b.htm Roche and Genentech will present a large number of abstracts on their broad oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 3 - 7, 2011. In order to assist you, we have prepared an ASCO planner providing an overview of oral and poster abstracts relevant to us, including indication of time and venue of the presentation. This planner can be downloaded from our website via http://www.roche.com/asco_plan_2011.pdf (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4857184 Fri, 20 May 2011 10:00:00 +0100 4857184 http://www.medworm.com/index.php?rid=4835273&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-05-19.htm Roche today announced final results from a randomised, multicentre, double-blind Phase II study with its investigational personalised medicine, MetMAb, in people with previously-treated advanced non-small cell lung cancer (NSCLC). MetMAb is a unique one-armed investigational antibody designed to target Met, a protein (or receptor) associated with a poor outcome in many cancers. The study showed that people whose tumours had high levels of Met, as determined by a companion diagnostic, lived twice as long without their disease getting worse (progression-free survival, [PFS]) when they received MetMAb plus Tarceva® (erlotinib) compared to Tarceva alone. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4835273 Thu, 19 May 2011 05:00:00 +0100 4835273 http://www.medworm.com/index.php?rid=4835274&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-05-18.htm Progress in advanced skin and lung cancers through personalised healthcare. New Phase III data for Avastin in ovarian cancer to be presented. Roche today announced that data showing new personalised therapeutic approaches for people with skin and lung cancer, plus new data with Avastin (bevacizumab) in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). At the meeting that is taking place June 3 to 7, 2011, in Chicago, Roche and Genentech’s investigational and approved cancer medicines will be featured in approximately 300 abstracts across more than 30 cancer types. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4835274 Wed, 18 May 2011 05:00:00 +0100 4835274 http://www.medworm.com/index.php?rid=4835275&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-05-17.htm Roche announced today that it has entered into agreements with Merck, known as MSD outside the United States, through their respective subsidiaries, to improve the treatment, diagnosis and awareness of chronic hepatitis C (HCV) infection in the United States. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4835275 Tue, 17 May 2011 15:30:00 +0100 4835275 http://www.medworm.com/index.php?rid=4808327&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-05-11.htm Roche today announced that the company submitted a New Drug Application for vemurafenib (RG7204, PLX4032) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application to the European Medicines Agency (EMA) for approval for people with BRAF V600 mutation-positive metastatic melanoma. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4808327 Wed, 11 May 2011 05:00:00 +0100 4808327 http://www.medworm.com/index.php?rid=4784869&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-05-05.htm Analyst briefing on data presented at ASCO: Sunday, 5 June 2011 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4784869 Thu, 05 May 2011 12:00:00 +0100 4784869 http://www.medworm.com/index.php?rid=4750206&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-04-26.htm Press release by Chugai (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4750206 Tue, 26 Apr 2011 06:00:00 +0100 4750206 http://www.medworm.com/index.php?rid=4738092&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-04-20b.htm Roche and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4738092 Wed, 20 Apr 2011 15:35:00 +0100 4738092 http://www.medworm.com/index.php?rid=4728289&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fhpv_kit_200px.jpg Roche announced today that the US Food and Drug Administration (FDA) has approved the cobas HPV (Human Papillomavirus) Test which identifies women at highest risk for developing cervical cancer. This test will help physicians make early, more accurate decisions about patient care, which may prevent many women from developing this deadly disease. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4728289 Wed, 20 Apr 2011 05:00:00 +0100 4728289 http://www.medworm.com/index.php?rid=4728290&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-04-19.htm Roche announced today that the Group's strong scientific publication track record from Genentech's and Roche's Research and Early Development units gRED and pRED continues. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4728290 Tue, 19 Apr 2011 05:00:00 +0100 4728290 http://www.medworm.com/index.php?rid=4728291&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-04-18.htm Medicine offers a new option for children living with a rare and severe form of arthritis. Roche today announced that the United States (U.S.) Food and Drug Administration (FDA) approved Actemra for the treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients two years of age and older. Actemra can be given alone or in combination with methotrexate in patients with SJIA. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4728291 Mon, 18 Apr 2011 05:00:00 +0100 4728291 http://www.medworm.com/index.php?rid=4716733&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-04-15.htm Approval would allow combination of Avastin with paclitaxel or Xeloda, offering more choice to physicians and patients. Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an extension to the Avastin (bevacizumab) breast cancer label in Europe. The application proposed the use of Avastin in combination with Xeloda (capecitabine) for the first-line treatment of women with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes and anthracyclines is not considered appropriate. Avastin is already approved in Europe in combination with paclitaxel chemotherapy in this setting. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4716733 Fri, 15 Apr 2011 11:30:00 +0100 4716733 http://www.medworm.com/index.php?rid=4711576&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-04-14.htm Group sales stable in local currencies (-9% in Swiss francs; +2% in US dollars) at 11.1 billion Swiss francs in first three months of 2011. Excluding Tamiflu, Group sales rise 2% (-7% in Swiss francs, +4% in US dollars). (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4711576 Thu, 14 Apr 2011 05:00:00 +0100 4711576 http://www.medworm.com/index.php?rid=4689042&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-04-07b.htm Roche will publish its Sales Results for the 1st Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday April 14th, 2011 07:00 CEST / 06:00 BST / 01:00 AM EDT / 22:00 PM PDT (evening before). Release will be e-mailed and posted on the Roche IR website http://ir.roche.com. Presentation slides will be posted on the Roche IR website http://ir.roche.com. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4689042 Thu, 07 Apr 2011 08:00:00 +0100 4689042 http://www.medworm.com/index.php?rid=4666907&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-04-01.htm Roche announced today that the results from two exploratory Phase IIb studies, dal-VESSEL and dal-PLAQUE, further support the promising safety profile of dalcetrapib, its first-in-class cholesteryl ester transfer protein (CETP) modulator. The studies investigated dalcetrapib’s effects on vascular function (dal-VESSEL) and on atherosclerotic disease progression (dal-PLAQUE) with the main goal of confirming that dalcetrapib does not have pro-inflammatory or pro-atherogenic effects, does not affect blood pressure and is generally well tolerated by patients treated for up to two years. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4666907 Fri, 01 Apr 2011 05:00:00 +0100 4666907 http://www.medworm.com/index.php?rid=4647511&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-03-28.htm Results consistent with data released last month showing patients with DME who received Lucentis achieved significant improvement in vision. Roche announced today that the second of two Phase III trials evaluating Lucentis (ranibizumab injection) in patients with diabetic macular edema (DME) met its primary endpoint. The primary endpoint of the study, known as RIDE, showed that after 24 months a significantly greater number of patients who received Lucentis, compared to those who received placebo (sham) injections, were able to read at least 15 additional letters on an eye chart than they could at the start of the study. The safety results were consistent with previous Lucentis Phase III trials and no new significant safety findings were observed. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4647511 Mon, 28 Mar 2011 05:00:00 +0100 4647511 http://www.medworm.com/index.php?rid=4618484&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-03-21.htm Roche today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer. The study met its primary endpoint (overall response rate), of showing vismodegib shrank tumours in a pre-defined percentage of people in the study. A preliminary safety assessment showed the most common adverse events were consistent with previous experience with vismodegib. A detailed safety assessment is ongoing. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4618484 Mon, 21 Mar 2011 06:00:00 +0100 4618484 http://www.medworm.com/index.php?rid=4607827&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-03-15b.htm Roche will publish its Sales Results for the 1st Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday April 14th, 2011 07:00 CEST / 06:00 BST / 01:00 AM EDT / 22:00 PM PDT (evening before) (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4607827 Tue, 15 Mar 2011 10:00:00 +0100 4607827 http://www.medworm.com/index.php?rid=4585419&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-03-15.htm Roche announced today the acquisition of PVT Probenverteiltechnik GmbH based in Waiblingen, Germany and of PVT Lab Systems, LLC based in Atlanta, Georgia, USA. PVT is a global market leader in providing customised automation and workflow solutions for in-vitro diagnostic (IVD) testing in large commercial and hospital laboratories. Under the terms of the agreement, Roche will pay PVT shareholders an upfront payment of EUR 65 million as well as up to EUR 20 million upon reaching performance-related milestones. The transaction is subject to customary closing conditions. PVT will become one of the competence centers inside Roche for the development and manufacturing of automation products. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4585419 Tue, 15 Mar 2011 07:45:00 +0100 4585419 http://www.medworm.com/index.php?rid=4567833&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-03-10b.htm Roche today announced that two-year results from a pivotal Phase III trial (RISE) showed patients with diabetic macular edema (DME) who received Lucentis (ranibizumab injection) experienced rapid and sustained improvement in vision compared to those who received a placebo (sham) injection. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4567833 Thu, 10 Mar 2011 13:15:00 +0100 4567833 http://www.medworm.com/index.php?rid=4567834&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-03-10.htm (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4567834 Thu, 10 Mar 2011 06:00:00 +0100 4567834 http://www.medworm.com/index.php?rid=4537777&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-03-02.htm Roche announced today that the European Commission confirmed that Avastin (bevacizumab) in combination with paclitaxel will remain a treatment option for women with metastatic breast cancer in Europe. The decision follows recent recommendations made by the Committee for Medicinal Products for Human Use (CHMP) that Avastin in combination with paclitaxel has been convincingly shown to enable women with metastatic breast cancer to live longer without their disease getting worse (progression-free survival) and that the combination is a valuable treatment option. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4537777 Wed, 02 Mar 2011 06:00:00 +0100 4537777 http://www.medworm.com/index.php?rid=4534174&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-03-01.htm Roche's Annual General Meeting, which was held today in Basel, has approved all of the Board of Directors' proposals. The 818 shareholders in attendance, representing 142,963,212 or 89.4% of a total of 160,000,000 bearer shares, approved the 2010 Annual Report and financial statements. They also authorised a dividend increase of 10% to 6.60 Swiss francs per share and non-voting equity. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4534174 Tue, 01 Mar 2011 12:45:00 +0100 4534174 http://www.medworm.com/index.php?rid=4519276&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-02-25.htm Roche announced that a study published online today in the American Journal of Clinical Pathology demonstrated the ability of the cobas HPV Test to individually detect HPV-16 and HPV-18, two of the highest risk HPV genotypes causing 70 percent of cervical cancer cases. The ATHENA (Addressing THE Need for Advanced HPV Diagnostics) study, which involved more than 47,000 women, validates the cobas HPV Test for triage of patients with an equivocal Pap test, a cytology category indicating atypical squamous cells of undetermined significance (ASC-US). This is the first in a series of papers to be published from the ATHENA study. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4519276 Fri, 25 Feb 2011 06:00:00 +0100 4519276 http://www.medworm.com/index.php?rid=4509248&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-02-23.htm Dear Investor, Please find attached a press release by Chugai: http://www.roche.com/inv-update-2011-02-23-annex.pdf Do not hesitate to contact us for any further questions. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4509248 Wed, 23 Feb 2011 06:00:00 +0100 4509248 http://www.medworm.com/index.php?rid=4486008&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-02-16.htm Roche today announced the initiation of a phase III study to investigate a subcutaneous formulation of MabThera (rituximab) for patients with CD20+ non-Hodgkin’s lymphoma (NHL). (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4486008 Wed, 16 Feb 2011 06:00:00 +0100 4486008 http://www.medworm.com/index.php?rid=4474473&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-02-14.htm Roche today announced that one of two Phase III studies evaluating monthly Lucentis (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint. DME is a serious complication of diabetes that affects up to 10 percent of people with the disease and can lead to blurred vision, severe vision loss and blindness. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4474473 Mon, 14 Feb 2011 06:00:00 +0100 4474473 http://www.medworm.com/index.php?rid=4447561&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-02-08.htm Roche announced today that OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4447561 Tue, 08 Feb 2011 06:00:00 +0100 4447561 http://www.medworm.com/index.php?rid=4426200&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-02-02b.htm Following the publication of Chugai's official 2010 results, Roche offers this investor update which reconciles these results with the results for Chugai published by Roche as part of the Roche Group's 2010 results. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4426200 Wed, 02 Feb 2011 09:00:00 +0100 4426200 http://www.medworm.com/index.php?rid=4426201&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-02-02.htm Mid-single digit sales growth in local currencies excluding Tamiflu - Strong profit growth - Promising late stage pharmaceutical pipeline of twelve new molecular entities (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4426201 Wed, 02 Feb 2011 06:00:00 +0100 4426201 http://www.medworm.com/index.php?rid=4416255&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-01-31.htm Roche today announced that the U.S. Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) as a maintenance treatment for patients with advanced follicular lymphoma who responded to initial treatment with Rituxan/MabThera plus chemotherapy (induction treatment). This milestone follows the clearance of MabThera for this indication by the European Commission in October 2010. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4416255 Mon, 31 Jan 2011 06:00:00 +0100 4416255 http://www.medworm.com/index.php?rid=4408237&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-01-28.htm Roche today announced that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study met its primary endpoint. At a planned interim analysis it was shown that compared to platinum-based chemotherapy Tarceva® (erlotinib) significantly extended the time people with newly diagnosed advanced non small cell lung cancer (NSCLC) with EGFR (epidermal growth factor receptor) activating mutations lived without their disease getting worse (progression-free survival or PFS). A preliminary safety analysis showed the safety profile was consistent with previous studies of Tarceva. Data will be submitted for presentation at a future medical meeting. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4408237 Fri, 28 Jan 2011 06:00:00 +0100 4408237 http://www.medworm.com/index.php?rid=4365771&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-01-19b.htm Roche will publish its Full Year Results for 2010 prior to the opening of the Swiss Stock Exchange on 2 February at 7:00 CET / 6:00 GMT / 1:00 AM EST. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4365771 Wed, 19 Jan 2011 10:00:00 +0100 4365771 http://www.medworm.com/index.php?rid=4365772&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-01-19.htm Roche today announced that BRIM3, a Phase III clinical study of RG7204 (PLX4032), met its co-primary endpoints showing a significant survival benefit in people with previously untreated BRAF V600 mutation-positive metastatic melanoma. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4365772 Wed, 19 Jan 2011 06:00:00 +0100 4365772 http://www.medworm.com/index.php?rid=4357815&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-01-17.htm Erich Hunziker (born 1953), Chief Financial Officer, Chief Information Officer and Deputy Head of the Corporate Executive Committee has decided to retire from Roche at the end of March 2011 and plans to focus on a number of board memberships. The Board of Directors of Roche Holding Ltd thanks Erich Hunziker for his many years of exceptional service and outstanding contributions to the Group’s success. The Board of Directors has appointed Alan Hippe to succeed Erich Hunziker as Chief Financial Officer. Alan Hippe will join Roche as a member of the Corporate Executive Committee as of April 2011. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4357815 Mon, 17 Jan 2011 06:00:00 +0100 4357815 http://www.medworm.com/index.php?rid=4311266&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-01-05.htm Roche today announced that the United States Food and Drug Administration has extended the ACTEMRA label to include inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis, when given in combination with methotrexate. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4311266 Wed, 05 Jan 2011 16:30:00 +0100 4311266 http://www.medworm.com/index.php?rid=4306838&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2011-01-04.htm Roche will publish its Full Year Results for 2010 prior to the opening of the Swiss Stock Exchange on 2 February at 7:00 CET / 6:00 GMT / 1:00 AM EST. Concurrently, the Full Year Presentation Slides and the Full Year Report will be available on the Roche website http://ir.roche.com. We would like to invite all interested parties to dial in or participate in any of the scheduled events outlined below: 2 February – 8:00 CET – Morning Telephone Conference 2 February – 15:00 GMT - Presentation in London (16:00 CET) 4 February – 12:30 PM EST – Presentation in New York (18:30 CET) (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4306838 Tue, 04 Jan 2011 13:00:00 +0100 4306838 http://www.medworm.com/index.php?rid=4269445&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-12-16.htm Roche confirmed that following the reviews of Avastin (bevacizumab) in metastatic breast cancer by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), the following regulatory announcements were made by the individual health authorities (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4269445 Thu, 16 Dec 2010 16:30:00 +0100 4269445 http://www.medworm.com/index.php?rid=4255799&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-12-13.htm Roche announced today that Walter Frey and Wolfgang Ruttenstorfer will not stand for re-election to the Board of Directors. Paul Bulcke (CEO of Nestlé), Christoph Franz (Chairman of the Executive Board & CEO Deutsche Lufthansa AG as of January 2011) and Peter Voser (CEO of Royal Dutch Shell plc) will be proposed for appointment to the Board of Directors at the 2011 Annual General Meeting. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4255799 Mon, 13 Dec 2010 06:00:00 +0100 4255799 http://www.medworm.com/index.php?rid=4247542&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-12-10.htm Phase II study evaluating a novel targeted combination regimen showed promising results in the neoadjuvant (pre-surgery) setting. Roche today announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination regimen of pertuzumab and Herceptin (trastuzumab) plus chemotherapy (docetaxel) in women with early-stage HER2-positive breast cancer. The data, presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), showed that the two antibodies plus docetaxel given in the neoadjuvant setting prior to surgery significantly improved the rate of complete tumour disappearance (pathological complete response rate, pCR, of 45.8 percent) in the breast by more than half compared to Herceptin plus docetaxel (pCR of 29. 0 percent), p=0.014. ... Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4247542 Fri, 10 Dec 2010 14:00:00 +0100 4247542 http://www.medworm.com/index.php?rid=4243614&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-12-09.htm Roche today will provide an update on its leading late-stage pipeline comprising twelve new molecular entities in key therapeutic areas. The London investor event will focus on major progress that has been achieved in recent months with Roche’s late-stage pipeline assets in the areas of oncology and CNS, as well as on further development plans of these potential breakthrough medicines. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4243614 Thu, 09 Dec 2010 06:00:00 +0100 4243614 http://www.medworm.com/index.php?rid=4231759&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-12-06.htm Roche announced today new Phase II efficacy data from the investigational compound GA101 (RG 1759) in relapsed/refractory Non-Hodgkin’s Lymphoma (NHL), a common type of blood cancer. GA101 is the first type II, glycoengineered anti-CD20 monoclonal antibody that has been specifically designed to enhance the destruction of cancerous B-cells either by activating other immune cells to attack the cancer cells or by inducing direct cell death. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4231759 Mon, 06 Dec 2010 06:00:00 +0100 4231759 http://www.medworm.com/index.php?rid=4231758&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-12-06b.htm Roche today presented eight-week results from a phase II study of RG16781, its investigational first-in-class glycine reuptake inhibitor (GRI) for the treatment of schizophrenia. The data showed a clinically meaningful reduction in the negative symptoms of schizophrenia, accompanied by beneficial changes in patients’ personal and social functioning. The study measured improvements in patients with predominantly negative symptoms of schizophrenia who received RG1678 in combination with second-generation antipsychotics. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4231758 Mon, 06 Dec 2010 06:00:00 +0100 4231758 http://www.medworm.com/index.php?rid=4229587&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-12-05.htm Rituxan/MabThera decreased the risk of needing later treatment with chemotherapy or radiotherapy by 80%. Roche announced today positive data from a Phase III study of Rituxan/MabThera (rituximab) in patients with advanced follicular lymphoma who did not have symptoms of disease (asymptomatic disease). Based on results of previous studies that showed no benefit of immediate chemotherapy after diagnosis, asymptomatic patients are managed by a “watchful waiting” approach and treatment for these patients usually does not begin until specific symptoms occur or their disease worsens. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4229587 Sun, 05 Dec 2010 13:00:00 +0100 4229587 http://www.medworm.com/index.php?rid=4222759&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-12-02.htm The Roche Investor Relations team would like to invite you to a Late-stage pipeline event that will take place in London, 9 December 2010, starting at 09:00 GMT at the London Stock Exchange. The event will provide an opportunity to discuss the clinical data and the development plans for the late-stage compounds in the Roche oncology and CNS development pipeline. The update will focus on the data presented at this year’s European Society for Medical Oncology (ESMO), European committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), International Melanoma Congress, American Society of Hematology (ASH) and the American College of Neuropsychopharmacology (ACNP). (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4222759 Thu, 02 Dec 2010 09:00:00 +0100 4222759 http://www.medworm.com/index.php?rid=4194119&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-11-23.htm Molecular assay aims to enhance personalized treatment with Tarceva by detecting EGFR activating mutations. Roche announced today that it has obtained a worldwide sublicense from Genzyme Corporation to develop a diagnostic assay for the detection of Epidermal Growth-Factor Receptor (EGFR) mutations. At the same time, Roche and OSI Pharmaceuticals, Inc. (OSI) have agreed to collaborate on the development of a PCR- based companion diagnostic test to identify people with non-small cell lung cancer (NSCLC) that harbors EGFR activating mutations. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4194119 Tue, 23 Nov 2010 06:00:00 +0100 4194119 http://www.medworm.com/index.php?rid=4173654&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-11-17.htm Measures aim to strengthen innovation and ensure sustained success in a fast changing market environment. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4173654 Wed, 17 Nov 2010 06:00:00 +0100 4173654 http://www.medworm.com/index.php?rid=4173655&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-11-17b.htm A conference call for investors and analysts will be held today, Wednesday, 17th November, 2010 to discuss implementation plans for Roche’s Operational Excellence Program at 15:00 – 16:00 CET / 14:00 – 15:00 GMT / 9:00 – 10:00 AM EST / 06:00 – 07:00 AM PST (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4173655 Wed, 17 Nov 2010 05:59:00 +0100 4173655 http://www.medworm.com/index.php?rid=4146788&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-11-09.htm The Roche Investor Relations team would like to invite you to a Late-stage pipeline event that will take place in London, 9 December 2010, starting at 09:00 BST at the London Stock Exchange. The event will provide an opportunity to discuss the clinical data and the development plans for the late-stage compounds in the Roche oncology and CNS development pipeline. The update will focus on the data presented at this year’s European Society for Medical Oncology (ESMO), European committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), International Melanoma Congress, American Society of Hematology (ASH) and the American College of Neuropsychopharmacology (ACNP). (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4146788 Tue, 09 Nov 2010 13:00:00 +0100 4146788 http://www.medworm.com/index.php?rid=4137043&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-11-04.htm Roche today announced results from a Phase II clinical study of RG7204 (PLX4032), an investigational first-in-class molecule designed to selectively inhibit a cancer-causing, mutated form of the BRAF protein found in approximately half of metastatic melanoma tumors. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4137043 Thu, 04 Nov 2010 22:05:00 +0100 4137043 http://www.medworm.com/index.php?rid=4113403&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-10-29.htm Roche announced today that the European Commission has approved the use of MabThera (rituximab) as a maintenance treatment for people suffering from follicular lymphoma who have responded to initial induction therapy. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4113403 Fri, 29 Oct 2010 05:00:00 +0100 4113403 http://www.medworm.com/index.php?rid=4092557&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-10-21b.htm Biogen Idec and Genentech, Inc. a wholly owned member of the Roche Group today announced that they have agreed to amend their collaboration on antibodies targeting CD20. The companies have agreed that Genentech will have responsibility for the further development of ocrelizumab in multiple sclerosis (MS). Genentech will fund 100% of the costs going forward and will be responsible for development and commercialization. Biogen Idec will receive tiered, double-digit royalties on US sales of ocrelizumab that will approximate its current 30% interest in the compound. Further, the companies have agreed that the commercialization of ocrelizumab will not impact the current profit share of Rituxan (rituximab). (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4092557 Thu, 21 Oct 2010 20:01:00 +0100 4092557 http://www.medworm.com/index.php?rid=4092558&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-10-21.htm First targeted medicine shown to improve overall survival in HER2-positive stomach and gastroesophageal junction cancers. Roche today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic cancer of the stomach or gastroesophageal junction, in men and women who have not received prior medicines for their metastatic disease. People diagnosed with metastatic stomach cancer should have the HER2 status of their tumors determined, as only patients with HER2-positive disease are eligible for treatment with Herceptin plus chemotherapy. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4092558 Thu, 21 Oct 2010 05:00:00 +0100 4092558 http://www.medworm.com/index.php?rid=4075932&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-10-18.htm Roche today announced that it has submitted a supplemental Biologics License Application (sBLA) to the United States (US) Food and Drug Administration (FDA) and an Accelerated Assessment application to the European Medicines Agency (EMA) to extend the license indication of ACTEMRA (known as RoACTEMRA in Europe) for the treatment of systemic Juvenile Idiopathic Arthritis (sJIA). (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4075932 Mon, 18 Oct 2010 05:00:00 +0100 4075932 http://www.medworm.com/index.php?rid=4070496&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-10-15.htm We're pleased to invite you to a conference call followed by Q&A on the updates to Core Results Reporting . The call will take place on Friday 22nd October, 2010 starting at 10:00 am CEST. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4070496 Fri, 15 Oct 2010 14:30:00 +0100 4070496 http://www.medworm.com/index.php?rid=4070497&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-10-15b.htm Roche and Biogen Idec (NASDAQ: BIIB) today announced 24-week results1 from a phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form2 of the disease. Ocrelizumab demonstrated a significant reduction in disease activity as measured by brain lesions and relapse rate. Patients with RRMS suffer from relapses and disabling symptoms caused by nerve damage which can significantly affect their quality of life. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4070497 Fri, 15 Oct 2010 13:30:00 +0100 4070497 http://www.medworm.com/index.php?rid=4070498&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-10-14.htm Group sales increase 2% in local currencies (-1% in Swiss francs; 3% in US dollars) to 36.1 billion Swiss francs in first nine months of 2010. Excluding Tamiflu, Group sales rise 6% (3% in Swiss francs, 7% in US dollars). (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4070498 Thu, 14 Oct 2010 05:00:00 +0100 4070498 http://www.medworm.com/index.php?rid=4054561&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-10-11b.htm Encouraging new data released at ESMO congress. Ovarian cancer: Data from second positive phase III study of Avastin (ICON7) add further evidence to the potential of Avastin in ovarian cancer where there have been few major treatment advances in the past decade. Metastatic breast cancer: T-DM1 achieves efficacy comparable to standard of care while significantly reducing the burden of typical side effects associated with conventional chemotherapy. Roche announced today that new data released at the 35th Congress of the European Society of Medical Oncology (ESMO) congress continue to support Roche’s development programs for Avastin in ovarian cancer and T-DM1 in HER2-positive breast cancer. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4054561 Mon, 11 Oct 2010 13:00:00 +0100 4054561 http://www.medworm.com/index.php?rid=4054562&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-10-11.htm Collaboration is based on recent DKFZ discovery suggesting cervical cancer risk may be more precisely determined. Roche and the German Cancer Research Center (DKFZ) announced today that they have entered into a research collaboration to enable more specific prediction of a woman’s risk for developing cervical cancer. The collaboration is based on recent DKFZ research indicating that the relative amounts of specific spliced viral RNA molecules (i.e., RNA markers) in HPV-infected cells enable highly accurate discrimination of cervical cancer and high-grade (pre-cancer) from low-grade cervical lesions. RMD and DKFZ initiated the three-year collaboration in September 2010. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4054562 Mon, 11 Oct 2010 06:00:00 +0100 4054562 http://www.medworm.com/index.php?rid=4052298&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-10-09.htm Important new data in lung cancer presented at ESMO, including further evidence of strong efficacy of Tarceva in lung cancer with genetic mutations. MetMAb plus Tarceva in lung cancer patients: preliminary data showed a pre-specified group of patients lived nearly twice as long without their disease getting worse than those who received placebo plus Tarceva. Tarceva in people with a distinct form of lung cancer: helped patients live almost three times longer without their disease getting worse compared to patients who received traditional chemotherapy. Roche today announced new data released at the 35th European Society for Medical Oncology (ESMO) congress showing significant progress for people living with lung cancer. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4052298 Sat, 09 Oct 2010 09:00:00 +0100 4052298 http://www.medworm.com/index.php?rid=4038749&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-10-07b.htm Roche will publish its Sales Results for the 3rd Quarter of 2010 prior to the opening of the Swiss Stock Exchange on Thursday 14th October, 2010. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4038749 Thu, 07 Oct 2010 08:00:00 +0100 4038749 http://www.medworm.com/index.php?rid=4038750&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-10-07.htm Roche today announced that it has bought full worldwide development and commercialization rights to danoprevir (RG7227/ITMN-191) from InterMune, Inc. (NASDAQ: ITMN) for USD 175 million. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4038750 Thu, 07 Oct 2010 05:00:00 +0100 4038750 http://www.medworm.com/index.php?rid=4029357&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-10-04.htm cobas TaqScreen DPX Test offers real-time discrimination in a single assay. Roche announced today that the cobas TaqScreen DPX Test for use on the cobas s 201 system is now available with the CE Mark. It is the first IVD test to offer complete coverage of all human genotypes of parvovirus B19 (B19V) and hepatitis A virus (HAV) in one assay. The test is a state-of-the-art, in-vitro nucleic acid amplification technology (NAT) test which simultaneously quantifies B19V genotypes 1, 2 and 3 DNA and detects HAV genotypes I, II and III RNA in individual samples or pooled plasma samples of human origin. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4029357 Mon, 04 Oct 2010 07:30:00 +0100 4029357 http://www.medworm.com/index.php?rid=4000216&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-09-24b.htm Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the use of MabThera (rituximab) as maintenance treatment for people suffering from follicular lymphoma who have responded to induction therapy. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4000216 Fri, 24 Sep 2010 12:55:00 +0100 4000216 http://www.medworm.com/index.php?rid=4000217&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-09-24.htm Roche announced today that on behalf of the European Medicines Agency (EMA), the Committee for Medicinal Products for Human Use (CHMP) has started a review of Avastin® in combination with paclitaxel or docetaxel for the first-line treatment of metastatic breast cancer in view of data from the RIBBON-1 study. An application for a license extension based on the RIBBON-1 study is currently under review by the EMA. Roche is committed to working closely with the CHMP to make sure they have all the information they require for this review of Avastin in the first-line treatment of metastatic breast cancer. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=4000217 Fri, 24 Sep 2010 12:54:00 +0100 4000217 http://www.medworm.com/index.php?rid=3982634&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-09-20.htm Roche will publish its Sales Results for the 3rd Quarter of 2010 prior to the opening of the Swiss Stock Exchange on Thursday 14th October, 2010. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=3982634 Mon, 20 Sep 2010 08:00:00 +0100 3982634 http://www.medworm.com/index.php?rid=3981680&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-09-18b.htm Roche today announced the topline results of a second phase III trial evaluating the use of Avastin (bevacizumab) plus chemotherapy in the adjuvant treatment (immediately after surgery) of early-stage colon cancer. The trial compared the efficacy and safety of Avastin plus chemotherapy to chemotherapy alone. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=3981680 Sat, 18 Sep 2010 14:01:00 +0100 3981680 http://www.medworm.com/index.php?rid=3981681&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-09-18.htm Genentech, Inc., a member of the Roche Group, today announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=3981681 Sat, 18 Sep 2010 14:00:00 +0100 3981681 http://www.medworm.com/index.php?rid=3963884&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-09-13.htm Roche Diagnostics announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the cobas® 8000 modular analyzer series, a Serum Work Area solution designed for diagnostic laboratories with a workload of 3-15 million clinical chemistry / immunochemistry tests per year. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=3963884 Mon, 13 Sep 2010 15:30:00 +0100 3963884 http://www.medworm.com/index.php?rid=3949047&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-09-09.htm Roche has been named Supersector Leader in Healthcare in the Dow Jones Sustainability Indexes (DJSI) for the second year running. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=3949047 Thu, 09 Sep 2010 10:15:00 +0100 3949047 http://www.medworm.com/index.php?rid=3926857&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-09-03.htm Roche today announced the launch of a Group-wide Operational Excellence initiative. In view of mounting pressures to curb healthcare costs – especially in the United States and Europe – together with recent developments in late-stage projects in the Roche pipeline, this initiative aims to adapt cost structures and accelerate productivity improvements Group-wide. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=3926857 Fri, 03 Sep 2010 05:00:00 +0100 3926857 http://www.medworm.com/index.php?rid=3918341&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-08-31.htm The Transnet Foundation in South Africa and Roche today unveiled a refurbished health clinic aboard the Phelophepa Healthcare train, a primary health facility on rails. The Transnet owned train provides primary healthcare services to South Africa’s most remote rural areas, including eye and dental care, psychiatric support, cancer, diabetes and hypertension screening, as well as health education programmes. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=3918341 Tue, 31 Aug 2010 05:00:00 +0100 3918341 http://www.medworm.com/index.php?rid=3905782&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-08-27.htm Roche expects a global regulatory submission mid 2012. Roche today announced that the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for the company’s trastuzumab-DM1 (T-DM1) Biologics License Application (BLA). As planned Roche will continue with its ongoing Phase III EMILIA registration study. Roche will continue to work with the FDA and expects a global regulatory submission of T-DM1 mid 2012. The BLA submitted in July 2010 requested accelerated approval for T-DM1 based on the results of a single-arm Phase II study, which showed T-DM1 shrank tumors in one-third of women with advanced HER2 positive breast cancer, who had received on average seven prior medicines, including two HER2 targeted agents. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=3905782 Fri, 27 Aug 2010 05:00:00 +0100 3905782 http://www.medworm.com/index.php?rid=3891127&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-08-23.htm Acquisition further strengthens Roche’s global leadership in tissue-based cancer diagnostics and research. Roche announced today that it has signed an agreement under which Ventana Medical Systems Inc., a member of the Roche Group, will acquire 100 percent of BioImagene, Inc., a privately held company based in Sunnyvale, California. The purchase price is approximately 100 million US dollars on a debt-free basis. The transaction is subject to customary closing conditions and is expected to close in the coming weeks. (Source: Roche Investor Update) Roche Investor Update news http://www.medworm.com/rss/comments.php?id=3891127 Mon, 23 Aug 2010 05:00:00 +0100 3891127